Fluorothymidine F-18 PET in Diagnosing Patients with Intermediate or High Grade Soft Tissue Sarcoma

Inclusion Criteria

• Participants must have histological evidence of an intermediate or high grade soft tissue sarcoma (STS) of any stage
• Participants must have measurable disease, defined as at least one lesion that can be accurately measured in at least one dimension as >= 1 cm with CT scan or MRI
• Prior resection is allowed if there is measurable gross disease and the subject plans to have neoadjuvant radiotherapy followed by resection
• Eastern Cooperative Oncology Group (ECOG) performance status =< 4, Karnofsky performance status >= 40%
• Creatinine =< 3 x upper limit of normal (ULM)
• Blood urea nitrogen (BUN) =< 3 x ULN
• Participants should be willing and able to have both PET-CT scans
• Participants should be eligible for and plan to undergo neoadjuvant radiation therapy and should be seen by a radiation oncologist prior to beginning the study; radiation at an outside facility will be allowed
• Participants should be eligible for and plan to have resection with a surgeon specializing in STS at Oregon Health and Science University (OHSU) and should be seen by said surgeon prior to beginning the study
• Participants should have a life expectancy that is greater than the study duration
• Participants should be willing to use adequate contraception from the time of the first PET-CT scan to 6 months after radiotherapy finishes; should a woman become pregnant while participating in this study, she should inform her treating physician immediately
• Women with childbearing potential must have a negative pregnancy test before each PET-CT scan
• Participants should have the ability to understand and the willingness to sign a written informed consent document
• Participants must sign a study specific consent form prior to registration

Exclusion Criteria

• Patients with uncontrolled intercurrent illness including, but not limited to, ongoing or active infection or significant inflammation at treatment site or psychiatric illness/social situations that would limit compliance with study requirements or whose lab values do not meet the criteria above are excluded
• Pregnant women are excluded from this study because radiation is a known teratogen
• Breast feeding women are excluded from this study because there is an unknown but potential risk for adverse events in nursing infants secondary to administration of 18F-FLT to the mother
• Patients receiving chemotherapy during the course of radiation are excluded
• Patients whose weights exceed the tolerance of the table are excluded; the weight limit at OHSU is 450 pounds (lbs)